title: The next questions in chronic myeloid leukaemia and their answers.
abstract: OBJECTIVE
  In this review, we analyze some of the topical issues in the clinical management of chronic myeloid leukaemia (CML).
  
  
  RESULTS
  In recent years, the management of CML patients has increased in complexity as molecular monitoring has brought to the clinical scene new therapeutic targets and the second-generation tyrosine kinase inhibitors have been licensed for first-line use.
  
  
  CONCLUSIONS
  In this article, we will try to answer some of the questions that a practising physician may face in clinical practice, such as: What should be the aim of therapy? What is the best front-line therapy? Which patients should receive an allogeneic stem cell transplant?
authors: Department of Haematology, Imperial College London, Hammersmith Hospital London, UK. d.marin@imperial.ac.uk
authors: David
authors: D
authors: Marin
authors: Antonia
authors: A
authors: Rotolo
authors: Dragana
authors: D
authors: Milojkovic
authors: John
authors: J
authors: Goldman
mesh_terms: D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D058990:Molecular Targeted Therapy; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D033581:Stem Cell Transplantation; D014184:Transplantation, Homologous
chemical_list: D047428:Protein Kinase Inhibitors